Advair

Mylan NV (NASDAQ: MYL)’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism. The Rating Leerink analyst Ami Fadia upgraded Mylan from Market Perform to Outperform and maintained a $52 price target. The Thesis By Leerink’s...

The health care sector, the third-largest sector weight in the S&P 500, is bouncing back in an impressive fashion this year after posting its first annual loss last year since 2008. While diversified health care exchange traded-funds are up 14 percent or more year to date, some more focused...

Commenting on Mylan N.V. (NASDAQ: MYL), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. That said, the firm thinks Mylan's chances are better than current market expectations. Analysts...

In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...

Shares of Theravance Inc (NASDAQ: THRX) fell more than 12 percent Wednesday morning after the company's commercial partner, GlaxoSmithKline plc (ADR) (NYSE: GSK), disclosed topline results from SUMMIT. Theravance's trial attempted to prove survival benefits for Breo in COPD patients and failed to...